Blog

What Transparency Means to Me, as the Founder of Bioethics International and the Good Pharma Scorecard

As the founder of the nonprofit Bioethics International and the Good Pharma Scorecard , I have been working on developing standards for clinical trial transparency and benchmarking the performance of new drugs and drug companies against those standards. Our goal is to improve ethics, trustworthiness, and patient-centricity/engagement in the development […]

Read more

BEI Update 3: Expanded Access, interns, and working w patient groups

Here is our 2 week update on BEI’s progress advancing ethics, transparency and patient-centricity in the the pharmaceutical sector: Our paper characterizing expanded access programs for experimental drugs (also known as compassionate use) was accepted into BMC. The paper is co-authored by Jennifer Miller, Arthur Caplan, Ken Moch, and Joseph Ross. Two new summer interns […]

Read more

BEI update 2: 2014 GPS transparency rankings submitted to journal, data-sharing standards, new team members

These last two weeks Bioethics International (BEI) has been busy advancing ethics, transparency and patient-centricity in the pharmaceutical sector, by: Submitting our 2014 Good Pharma Scorecard (GPS) rankings for review and publication in a medical journal.  The 2014 rankings will uniquely include a new company ranking to accompany the drug rankings on clinical trial […]

Read more

BEI update 1: Drug & company rankings, Times Square billboard & conference

BEI is returning to its roots and blogging again.  BEI started as a blog in 2005, called Ethics Illustrated. We’ll kick off our blogging with bi-weekly updates on our efforts.  This month, we’ve been: Finishing the clinical trial transparency rankings of drugs approved by the FDA in 2014 and large drug companies.  We held our bi-annual meeting with […]

Read more